drugset

drugset / Trial / NCT06837896

Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer

NCT06837896 ↗

Phase 3 Not yet recruiting 110 enrolled Qilu Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the efficacy and safety of QLG1080 in patients with hormone-sensitive advanced prostate cancer.

Timeline

Start: 2025-02
Primary completion: 2026-11
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	QLG1080	Unknown	—	Oral

Indications